Cargando…

Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease

Background: We investigated how the non-medical switching (NMS) between Etanercept (ETN)/originator and SB4/biosimilar affects treatment efficacy in a rheumatic disease (RD) cohort, evaluating some laboratory parameters as loss of efficacy predictors after NMS. Methods: We enrolled 124 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Benucci, Maurizio, Damiani, Arianna, Russo, Edda, Li Gobbi, Francesca, Grossi, Valentina, Amedei, Amedeo, Infantino, Maria, Manfredi, Mariangela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316161/
https://www.ncbi.nlm.nih.gov/pubmed/35887671
http://dx.doi.org/10.3390/jpm12071174
_version_ 1784754739635814400
author Benucci, Maurizio
Damiani, Arianna
Russo, Edda
Li Gobbi, Francesca
Grossi, Valentina
Amedei, Amedeo
Infantino, Maria
Manfredi, Mariangela
author_facet Benucci, Maurizio
Damiani, Arianna
Russo, Edda
Li Gobbi, Francesca
Grossi, Valentina
Amedei, Amedeo
Infantino, Maria
Manfredi, Mariangela
author_sort Benucci, Maurizio
collection PubMed
description Background: We investigated how the non-medical switching (NMS) between Etanercept (ETN)/originator and SB4/biosimilar affects treatment efficacy in a rheumatic disease (RD) cohort, evaluating some laboratory parameters as loss of efficacy predictors after NMS. Methods: We enrolled 124 patients with RD (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis): 79 switchers from ETN/originator to SB4 and 45 naïve patients receiving SB4 (first biological treatment). At baseline, 6 (T1), and 12 months (T2), clinical and laboratory parameters were evaluated. Results: In naïve patients, TNF-α significantly increased at T1 in responders (NR) and non-responders (NNR). TNF-α was lower in NNR than in NR at T1 and T2. In NR and NNR, drug levels (DL) increased between T1 and T2. However, DLs were lower in NNR than in NR at T1 and T2. TNF-α was higher in switcher responders (SR) than in non-responders (SNR) at T1 and T2. In SNR, DLs were higher at baseline than in SR, but they decreased significantly at T1 and T2. Conclusions: We observed a decrease in DL and TNF-α levels after NMS in SNR. Moreover, in naïve patients, DL and TNF-α levels were higher in NR than in NNR. Monitoring DL and TNF-α levels may represent a future precision medicine approach to predict loss of efficacy after NMS.
format Online
Article
Text
id pubmed-9316161
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93161612022-07-27 Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease Benucci, Maurizio Damiani, Arianna Russo, Edda Li Gobbi, Francesca Grossi, Valentina Amedei, Amedeo Infantino, Maria Manfredi, Mariangela J Pers Med Article Background: We investigated how the non-medical switching (NMS) between Etanercept (ETN)/originator and SB4/biosimilar affects treatment efficacy in a rheumatic disease (RD) cohort, evaluating some laboratory parameters as loss of efficacy predictors after NMS. Methods: We enrolled 124 patients with RD (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis): 79 switchers from ETN/originator to SB4 and 45 naïve patients receiving SB4 (first biological treatment). At baseline, 6 (T1), and 12 months (T2), clinical and laboratory parameters were evaluated. Results: In naïve patients, TNF-α significantly increased at T1 in responders (NR) and non-responders (NNR). TNF-α was lower in NNR than in NR at T1 and T2. In NR and NNR, drug levels (DL) increased between T1 and T2. However, DLs were lower in NNR than in NR at T1 and T2. TNF-α was higher in switcher responders (SR) than in non-responders (SNR) at T1 and T2. In SNR, DLs were higher at baseline than in SR, but they decreased significantly at T1 and T2. Conclusions: We observed a decrease in DL and TNF-α levels after NMS in SNR. Moreover, in naïve patients, DL and TNF-α levels were higher in NR than in NNR. Monitoring DL and TNF-α levels may represent a future precision medicine approach to predict loss of efficacy after NMS. MDPI 2022-07-19 /pmc/articles/PMC9316161/ /pubmed/35887671 http://dx.doi.org/10.3390/jpm12071174 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Benucci, Maurizio
Damiani, Arianna
Russo, Edda
Li Gobbi, Francesca
Grossi, Valentina
Amedei, Amedeo
Infantino, Maria
Manfredi, Mariangela
Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease
title Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease
title_full Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease
title_fullStr Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease
title_full_unstemmed Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease
title_short Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease
title_sort predicting loss of efficacy after non-medical switching: correlation between circulating tnf-α levels and sb4 in etanercept to sb4 switchers and naïve patients with rheumatic disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316161/
https://www.ncbi.nlm.nih.gov/pubmed/35887671
http://dx.doi.org/10.3390/jpm12071174
work_keys_str_mv AT benuccimaurizio predictinglossofefficacyafternonmedicalswitchingcorrelationbetweencirculatingtnfalevelsandsb4inetanercepttosb4switchersandnaivepatientswithrheumaticdisease
AT damianiarianna predictinglossofefficacyafternonmedicalswitchingcorrelationbetweencirculatingtnfalevelsandsb4inetanercepttosb4switchersandnaivepatientswithrheumaticdisease
AT russoedda predictinglossofefficacyafternonmedicalswitchingcorrelationbetweencirculatingtnfalevelsandsb4inetanercepttosb4switchersandnaivepatientswithrheumaticdisease
AT ligobbifrancesca predictinglossofefficacyafternonmedicalswitchingcorrelationbetweencirculatingtnfalevelsandsb4inetanercepttosb4switchersandnaivepatientswithrheumaticdisease
AT grossivalentina predictinglossofefficacyafternonmedicalswitchingcorrelationbetweencirculatingtnfalevelsandsb4inetanercepttosb4switchersandnaivepatientswithrheumaticdisease
AT amedeiamedeo predictinglossofefficacyafternonmedicalswitchingcorrelationbetweencirculatingtnfalevelsandsb4inetanercepttosb4switchersandnaivepatientswithrheumaticdisease
AT infantinomaria predictinglossofefficacyafternonmedicalswitchingcorrelationbetweencirculatingtnfalevelsandsb4inetanercepttosb4switchersandnaivepatientswithrheumaticdisease
AT manfredimariangela predictinglossofefficacyafternonmedicalswitchingcorrelationbetweencirculatingtnfalevelsandsb4inetanercepttosb4switchersandnaivepatientswithrheumaticdisease